Please ensure Javascript is enabled for purposes of website accessibility

Why iRhythm Technologies Stock Is Crashing Today

By Keith Speights - Apr 12, 2021 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novitas' new Medicare reimbursement rates translate to significantly lower revenue for the cardiac care company.

What happened

Shares of iRhythm Technologies (IRTC 5.70%) were crashing 37.5% lower as of 12:01 p.m. EDT on Monday. The big decline came after the company responded to the publication of Medicare reimbursement rates by Novitas Solutions on Saturday.

iRhythm stated that these new rates would negatively impact its first-quarter revenue by $13 million. The company also said it wouldn't be able to provide its Zio XT service for cardiac monitoring to the Medicare fee-for-service segment if the rates aren't increased.

Cardiac monitor chart

Image source: Getty Images.

So what

Companies such as iRhythm are heavily dependent on the rates set by Medicare Administrative Contractors (MACs). It's not surprising that the healthcare stock would be hammered so hard after today's announcement.

iRhythm estimates that its full-year 2020 revenue would have been reduced by 15.6% if the rates recently set by Novitas had been in place throughout last year. The company said its gross margin would have fallen from 73.5% to 68.6%. In 2020, Medicare generated 27% of the company's total revenue.

Now what

iRhythm Technologies CEO Mike Coyle said, "We are extremely disappointed that Novitas did not reflect the appropriate clinical and economic value of long-term continuous ECG monitoring and Zio XT." The company said it's planning to discontinue serving this Medicare fee-for-service segment with its Zio XT service beginning in the second quarter.

However, iRhythm isn't completely giving up. Coyle said the company "will continue to work hard to secure more appropriate reimbursement for Medicare patients, including national pricing with CMS [Centers for Medicare and Medicaid Services], so we can continue to deliver the service to all potential patients who can benefit from it."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

iRhythm Technologies Stock Quote
iRhythm Technologies
IRTC
$149.72 (5.70%) $8.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.